CLDN4 and lung adenocarcinoma: Whereas 37 out of 64 (57.8%) malignant effusion (lung adenocarcinoma, MPM cases) were Claudin-4 positive, all cases of benign effusion with RMCs were Claudin-4 negative (Figure 1).